Načítá se...
Practical management of tumour lysis syndrome in venetoclax‐treated patients with chronic lymphocytic leukaemia
The treatment landscape in relapsed/refractory chronic lymphocytic leukaemia (CLL) has rapidly evolved over the past five years, with one such emergent treatment being the BCL2 inhibitor, venetoclax. This oral treatment has demonstrated significant clinical advantages in indicated patients, but rapi...
Uloženo v:
| Vydáno v: | Br J Haematol |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7154710/ https://ncbi.nlm.nih.gov/pubmed/31858596 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16345 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|